← Back to Search

Other

ALTO-300 in Depression

Phase 2
Waitlist Available
Research Sponsored by Alto Neuroscience
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured 6 times over 8 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial studies ALTO-300, a treatment, to understand its effects on various patients. Researchers aim to find indicators that show how effective ALTO-300 is.

Eligible Conditions
  • Depression

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured 6 times over 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured 6 times over 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To evaluate the safety of ALTO-300
To understand the relationship between baseline biology and clinical outcome to ALTO-300 using the Clinical Global Impression scale - Severity (CGI-S)
To understand the relationship between baseline biology and clinical outcome to ALTO-300 using the Montgomery-Åsberg Depression Rating Scale (MADRS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ALTO-300Experimental Treatment1 Intervention
ALTO-300 oral (PO) tablet; daily dosing 8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALTO-300 oral (PO) tablet
2021
Completed Phase 2
~100

Find a Location

Who is running the clinical trial?

Alto NeuroscienceLead Sponsor
10 Previous Clinical Trials
1,247 Total Patients Enrolled
9 Trials studying Depression
1,175 Patients Enrolled for Depression
~23 spots leftby Dec 2025